Atea Pharmaceuticals (NASDAQ:AVIR – Get Free Report) had its price target boosted by analysts at Morgan Stanley from $7.00 to $8.00 in a research note issued to investors on Monday, Benzinga reports. The firm currently has an “equal weight” rating on the stock. Morgan Stanley‘s price target would suggest a potential upside of 86.31% from the company’s previous close.
AVIR has been the topic of a number of other research reports. Wall Street Zen upgraded shares of Atea Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Saturday, September 12th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Atea Pharmaceuticals in a research note on Thursday, October 15th. One research analyst has rated the stock with a Strong Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and an average price target of $8.00.
Get Our Latest Stock Analysis on AVIR
Atea Pharmaceuticals Trading Down 0.1%
NASDAQ AVIR traded down $0.01 during trading hours on Monday, reaching $4.29. 12,433 shares of the company traded hands, compared to its average volume of 379,796. Atea Pharmaceuticals has a 12 month low of $2.92 and a 12 month high of $6.45. The stock has a market capitalization of $344.83 million, a PE ratio of -2.20 and a beta of 0.76. The company has a 50 day moving average of $4.79 and a two-hundred day moving average of $4.94.
Atea Pharmaceuticals (NASDAQ:AVIR – Get Free Report) last announced its quarterly earnings data on Monday, November 9th. The company reported ($0.40) earnings per share for the quarter, topping the consensus estimate of ($0.51) by $0.11. On average, equities research analysts anticipate that Atea Pharmaceuticals will post -1.91 earnings per share for the current year.
Institutional Investors Weigh In On Atea Pharmaceuticals
A number of institutional investors have recently made changes to their positions in AVIR. Empowered Funds LLC bought a new position in Atea Pharmaceuticals during the third quarter worth $475,000. Engineers Gate Manager LP acquired a new position in Atea Pharmaceuticals in the second quarter worth $78,000. Spark Investment Management LLC acquired a new position in Atea Pharmaceuticals in the second quarter worth $75,000. Headlands Technologies LLC bought a new stake in Atea Pharmaceuticals during the second quarter valued at $77,000. Finally, Wellington Management Group LLP increased its stake in Atea Pharmaceuticals by 262.7% during the second quarter. Wellington Management Group LLP now owns 206,785 shares of the company’s stock valued at $962,000 after purchasing an additional 149,776 shares during the last quarter. 86.67% of the stock is currently owned by institutional investors.
Atea Pharmaceuticals Company Profile
Atea Pharmaceuticals is a clinical-stage biopharmaceutical company focused on discovering and developing oral antiviral medicines for serious viral diseases. Its research centers on compounds intended to interfere with viral replication. The company’s investigational portfolio has included bemnifosbuvir, an oral antiviral candidate studied for COVID-19, as well as programs targeting other viral infections, including dengue. These medicines are investigational and are not established marketed treatments.
Featured Articles
- Five stocks we like better than Atea Pharmaceuticals
- Sandisk’s Sell-Off May Be Losing Steam, But the Biggest Risk Still Looms
- Meta’s Access to Capital Remains Strong, But Borrowing Is Becoming More Expensive
- 3 Large-Cap Stocks Are Outperforming the S&P 500 Without AI Hype
- Fossil Just Turned a Profit—Can Its Comeback Survive the Holidays?
Receive News & Ratings for Atea Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atea Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
